{
    "root": "c3ddfc92-11fa-4820-a29a-b979a8d55d5b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fluoxetine",
    "value": "20250514",
    "ingredients": [
        {
            "name": "FLUOXETINE HYDROCHLORIDE",
            "code": "I9W7N6B1KJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5119"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        }
    ],
    "indications": {
        "text": "fluoxetine indicated treatment : \u2022acute maintenance treatment major depressive disorder [ ( 14.1 ) ] . \u2022acute maintenance treatment obsessions compulsions patients obsessive compulsive disorder ( ocd ) [ ( 14.2 ) ] . \u2022acute maintenance treatment binge-eating vomiting behaviors patients moderate severe bulimia nervosa [ ( 14.3 ) ] . \u2022acute treatment panic disorder , without agoraphobia [ ( 14.4 ) ] . fluoxetine olanzapine combination indicated treatment : \u2022acute treatment depressive episodes associated bipolar disorder . \u2022treatment resistant depression ( major depressive disorder patients , respond 2 separate trials different antidepressants adequate dose duration current episode ) . fluoxetine monotherapy indicated treatment depressive episodes associated bipolar disorder treatment treatment resistant depression . using fluoxetine olanzapine combination , also refer section package insert symbyax \u00ae .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "obsessive compulsive disorder (DOID:10933)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10933"
            },
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "bulimia nervosa (DOID:12129)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12129"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            },
            {
                "text": "agoraphobia (DOID:593)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_593"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute treatment panic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_79276"
            },
            {
                "disease": "acute maintenance treatment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_497130"
            },
            {
                "disease": "severe bulimia nervosa",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_94075"
            }
        ]
    },
    "contraindications": {
        "text": "indication adult pediatric mdd ( 2.1 ) 20 mg/day ( initial dose ) 10 20 mg/day ( initial dose ) ocd ( 2.2 ) 20 mg/day ( initial dose ) 10 mg/day ( initial dose ) bulimia nervosa ( 2.3 ) 60 mg/day panic disorder ( 2.4 ) 10 mg/day ( initial dose ) depressive episodes associated bipolar disorder ( 2.5 ) oral combination olanzapine : 5 mg oral olanzapine 20 mg fluoxetine daily ( initial dose ) oral combination olanzapine : 2.5 mg oral olanzapine 20 mg fluoxetine daily ( initial dose ) treatment resistant depression ( 2.6 ) oral combination olanzapine : 5 mg oral olanzapine 20 mg fluoxetine daily ( initial dose ) \u2022 lower less frequent used patients hepatic impairment , elderly , patients concurrent disease multiple concomitant medications ( 2.7 ) fluoxetine capsules olanzapine combination : \u2022 adjustments made individual components according efficacy tolerability ( 2.5 , 2.6 ) \u2022 fluoxetine monotherapy indicated treatment depressive episodes associated bipolar disorder treatment resistant depression ( 2.5 , 2.6 ) \u2022 safety coadministration doses 18 mg olanzapine 75 mg fluoxetine evaluated adults ( 2.5 , 2.6 ) \u2022 safety coadministration doses 12 mg olanzapine 50 mg fluoxetine evaluated children adolescents ages 10 17 ( 2.5 )",
        "doid_entities": [
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "bulimia nervosa (DOID:12129)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12129"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "depression (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fluoxetine capsules usp , 40 mg * * white white powder filled size \u201c 0 \u201d hard gelatin capsules opaque light blue colored cap opaque white colored body imprinted \u201c sg \u201d cap \u201c 115 \u201d body black ink . bottles 30 ndc 68788-7741-03 bottles 60 ndc 68788-7741-06 bottles 90 bottles 100 ndc 68788-7741-09 ndc 68788-7741-01 * * fluoxetine base equivalent .",
    "adverseReactions": "using fluoxetine capsules olanzapine combination , also refer section package insert symbyax .",
    "indications_original": "Fluoxetine is indicated for the treatment of:\n                  \n                     \n                        \u2022Acute and maintenance treatment of Major Depressive Disorder       [see         Clinical Studies (14.1)]       .     \n                     \n                        \u2022Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)       [see         Clinical Studies (14.2)]       .     \n                     \n                        \u2022Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa       [see         Clinical Studies (14.3)]       .     \n                     \n                        \u2022Acute treatment of Panic Disorder, with or without agoraphobia       [see         Clinical Studies (14.4)]       .     \n                  \n                  Fluoxetine and Olanzapine in Combination is indicated for the treatment of:\n                  \n                     \n                        \u2022Acute treatment of depressive episodes associated with Bipolar I Disorder.\n                     \n                        \u2022Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode).\n                  \n                  Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression.    \n                     \n                     When using fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax       \u00ae.",
    "contraindications_original": "Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Treatment Resistant Depression ( 2.6 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) \u2022 A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: \u2022 Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 , 2.6 ) \u2022 Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder or treatment resistant depression ( 2.5 , 2.6 ) \u2022 Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults ( 2.5 , 2.6 ) \u2022 Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 )",
    "warningsAndPrecautions_original": "Fluoxetine Capsules USP, 40 mg** are white to off white powder filled in size \u201c0\u201d hard gelatin capsules with opaque light blue colored cap and opaque white colored body imprinted \u201cSG\u201d on cap and \u201c115\u201d on body with black ink.\n                        \n                           \n                           \n                           \n                              \n                                 \n                                    Bottles of 30\n                                 \n                                 \n                                    NDC 68788-7741-03\n                                 \n                              \n                              \n                                 \n                                    Bottles of 60\n                                 \n                                 \n                                    NDC 68788-7741-06\n                                 \n                              \n                              \n                                 \n                                    Bottles of 90\n                                    Bottles of 100\n                                 \n                                 \n                                    NDC 68788-7741-09\n                                    NDC 68788-7741-01\n                                 \n                              \n                           \n                        \n                        **Fluoxetine base equivalent.",
    "adverseReactions_original": "When using fluoxetine capsules and olanzapine in combination, also refer to the Contraindications section of the package insert for Symbyax.",
    "drug": [
        {
            "name": "Fluoxetine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5118"
        }
    ]
}